Compile Data Set for Download or QSAR
Report error Found 123 Enz. Inhib. hit(s) with all data for entry = 10812
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570745(US11440886, Example 81)
Affinity DataIC50: 1.15nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570694(US11440886, Example 41)
Affinity DataIC50: 1.22nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570762(US11440886, Example 100 | US11440886, Example 96)
Affinity DataIC50: 1.5nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570783(US11440886, Example 114)
Affinity DataIC50: 1.60nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570762(US11440886, Example 100 | US11440886, Example 96)
Affinity DataIC50: 2.40nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570775(US11440886, Example 106)
Affinity DataIC50: 2.70nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570754(US11440886, Example 88)
Affinity DataIC50: 2.80nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570708(US11440886, Example 49)
Affinity DataIC50: 2.90nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570774(US11440886, Example 105)
Affinity DataIC50: 3nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570763(US11440886, Example 97)
Affinity DataIC50: 3.70nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570756(US11440886, Example 90)
Affinity DataIC50: 3.80nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570750(US11440886, Example 85)
Affinity DataIC50: 3.80nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570652(US11440886, Example 18)
Affinity DataIC50: 4.5nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570653(US11440886, Example 19)
Affinity DataIC50: 4.60nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570655(US11440886, Example 21)
Affinity DataIC50: 4.60nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570696(US11440886, Example 43)
Affinity DataIC50: 4.90nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570646(US11440886, Example 13)
Affinity DataIC50: 4.90nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570639(US11440886, Example 5)
Affinity DataIC50: 5nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570657(US11440886, Example 23)
Affinity DataIC50: 5nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570722(US11440886, Example 59)
Affinity DataIC50: 5.10nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570721(US11440886, Example 58)
Affinity DataIC50: 5.5nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570641(US11440886, Example 7)
Affinity DataIC50: 5.70nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570725(US11440886, Example 61)
Affinity DataIC50: 6.20nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570693(US11440886, Example 40)
Affinity DataIC50: 6.80nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570755(US11440886, Example 89)
Affinity DataIC50: 6.90nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570744(US11440886, Example 80)
Affinity DataIC50: 7nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570706(US11440886, Example 47)
Affinity DataIC50: 7.10nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570746(US11440886, Example 82)
Affinity DataIC50: 7.5nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570734(US11440886, Example 70)
Affinity DataIC50: 8.10nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570695(US11440886, Example 42)
Affinity DataIC50: 8.20nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570784(US11440886, Example 115)
Affinity DataIC50: 9.90nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570726(US11440886, Example 62)
Affinity DataIC50: 10.2nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570649(US11440886, Example 16)
Affinity DataIC50: 10.3nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570727(US11440886, Example 63)
Affinity DataIC50: 11.1nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570659(US11440886, Example 25)
Affinity DataIC50: 11.5nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570765(US11440886, Example 101-2 | US11440886, Example 98...)
Affinity DataIC50: 12.5nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570759(US11440886, Example 93)
Affinity DataIC50: 12.9nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570654(US11440886, Example 20)
Affinity DataIC50: 13nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570667(US11440886, Example 32)
Affinity DataIC50: 13.9nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570771(US11440886, Example 103)
Affinity DataIC50: 14nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570713(US11440886, Example 53)
Affinity DataIC50: 15nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570716(US11440886, Example 56)
Affinity DataIC50: 16nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570651(US11440886, Example 17)
Affinity DataIC50: 16nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570640(US11440886, Example 6)
Affinity DataIC50: 19nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570656(US11440886, Example 22)
Affinity DataIC50: 20nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570647(US11440886, Example 14)
Affinity DataIC50: 21nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570658(US11440886, Example 24)
Affinity DataIC50: 23nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570642(US11440886, Example 8)
Affinity DataIC50: 23nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570643(US11440886, Example 9)
Affinity DataIC50: 25nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
E-Nitiate Biopharmaceuticals (Hangzhou)

US Patent
LigandPNGBDBM570705(US11440886, Example 46)
Affinity DataIC50: 25nMAssay Description:The inhibitory effect of the compounds on human PDE4B1 enzyme activity was determined by quantifying the 5′-adenosine monophosphate (5′-A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

Displayed 1 to 50 (of 123 total ) | Next | Last >>
Jump to: